Dow Jones

39,112.16

-0.76%

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
NASDAQ
Eloxx Pharmaceuticals Inc (ELOX)
Eloxx Pharmaceuticals Inc (ELOX) Noticias

ELOX

Eloxx Pharmaceuticals (ELOX)

Eloxx Pharmaceuticals Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ELOX

1 2 3 4 5 6 7 8 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
16/04/2024	06:30	GlobeNewswire Inc.	Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
01/04/2024	15:02	Edgar (US Regulatory)	Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
29/03/2024	15:11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
21/03/2024	13:20	Edgar (US Regulatory)	Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
13/03/2024	10:42	GlobeNewswire Inc.	Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
26/01/2024	15:33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
24/01/2024	20:44	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
24/01/2024	16:11	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
13/11/2023	15:15	GlobeNewswire Inc.	Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
09/10/2023	07:00	GlobeNewswire Inc.	Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
20/09/2023	12:26	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
19/09/2023	07:00	GlobeNewswire Inc.	Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
18/09/2023	06:00	GlobeNewswire Inc.	Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
07/09/2023	08:00	GlobeNewswire Inc.	Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
14/08/2023	07:30	GlobeNewswire Inc.	Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
14/08/2023	07:00	GlobeNewswire Inc.	Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
11/08/2023	15:05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
03/08/2023	08:26	GlobeNewswire Inc.	Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
10/07/2023	08:00	GlobeNewswire Inc.	Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
28/06/2023	08:00	GlobeNewswire Inc.	Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
23/06/2023	05:01	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
21/06/2023	12:30	GlobeNewswire Inc.	Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
21/06/2023	08:00	GlobeNewswire Inc.	Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
14/06/2023	15:53	GlobeNewswire Inc.	Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
01/06/2023	08:10	GlobeNewswire Inc.	Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
24/05/2023	07:41	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
24/05/2023	07:00	GlobeNewswire Inc.	Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
15/05/2023	15:30	GlobeNewswire Inc.	Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
02/05/2023	07:00	GlobeNewswire Inc.	Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
28/04/2023	15:04	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc